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Abstract. Background: Multi-transfused thalassemia major (TM) patients frequently develop 
severe endocrine complications, mainly due to iron overload, anemia, and chronic liver disease, 
which require prompt diagnosis, treatment and follow-up by specialists.  
The most common endocrine complication documented is hypogonadotropic hypogonadism 
which increases with age and associated comorbidities. It is thus important for physicians to 
have a clear understanding of the pathophysiology and management of this disorder. Also to be 
aware of the side effects, contraindications and monitoring of sex steroid therapy. In this paper, 
practical ICET-A recommendations for the management of hypogonadism in adult females with 
TM are addressed. 
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Methods: In March 2015, the Coordinator of the International Network of Clinicians for 
Endocrinopathies in Thalassemia and Adolescent Medicine (ICET-A) conducted a two-step 
survey to assess the attitudes and practices of doctors in the ICET-A network taking care of 
adult female TM patients with hypogonadism. They were clinically characterized by the absence 
of pubertal development or discontinuation or regression of the maturation of secondary sex 
characteristics, and biochemically by persistent low FSH, LH and estradiol levels. Recently a 
supplementary survey on adult female hypogonadism in TM was undertaken within the ICET-A 
network. 
Results: The completed questionnaires were returned by 16 of 27 specialists (59.2%) following 
590 female TM patients over the age of 18 years; 315 patients (53.3%) had hypogonadism, and 
only 245 (74.6%) were on hormone replacement therapy (HRT). Contraceptive oral pills (COC) 
were the first treatment choice in 11 centers (68.7%). A wide range of COCs was used with 
different progestin contents. In general, the patients’ compliance to treatment was reported as 
good in 81.2 % of centers. The frequency of required tests for follow-up HRT, in addition to the 
regular check-up for thalassemia, was variable in the participating centers. 
Conclusions: Doctors taking care of TM patients should have sound knowledge of the 
pathophysiology of hypogonadism in adult females with TM. They should know the potential 
effects of HRT including advantages and disadvantages of estrogen and progestins. Moreover, 
they should keep in consideration the emotional needs of these patients dreaming of attaining a 
full pubertal development. 
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Introduction. Multi-transfused thalassemia major 
(TM) patients frequently develop severe endocrine 
complications mainly due to iron overload, 
anemia, and chronic liver disease, which require 
prompt diagnosis, treatment and close follow-up 
by specialists.
1-3
 
The most common endocrine complication 
documented in adult TM patients is 
hypogonadotropic hypogonadism which increases 
with age and the associated comorbidities.
3
 In 
adult females TM patients, hypogonadism is 
clinically diagnosed by the absence of pubertal 
development, or discontinuation or regression of 
the maturation of secondary sex characteristics due 
to pituitary dysfunction and/or gonadal damage, 
secondary to iron overload.
4
 The incidence rate of 
hypogonadism, in both sexes, varies considerably 
between countries and much more between 
specialized centers, ranging from around 50% and 
may even approach 100%.
1-4
 
Evidence suggests that more severe defects are 
related to a higher rate of iron loading possibly 
due to increased vulnerability to free radical 
toxicity.
1-4
 
Hormone replacement therapy (HRT) in 
females with hypogonadism aims to alleviate 
symptoms of estrogen deficiency and prevent 
long-term complications such as osteoporosis.
5
 
However, HRT has been linked to various risks 
and the debate regarding its risk-benefit ratio 
continues. The principal risks of HRT are 
thromboembolic disease, stroke, cardiovascular 
events, gallbladder disease, breast cancer and 
endometrial hyperplasia or endometrial cancer.
6
 
In March 2015, the Coordinator (VDS) of the 
International Network of Clinicians for 
Endocrinopathies in Thalassemia and Adolescent 
Medicine (ICET-A) conducted a two-step survey 
to assess the attitudes and practices of doctors 
taking care of adult TM with hypogonadism. In 
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this report, we present the results of the study and 
the practical recommendations for hypogonadism 
in adult females with TM based on literature 
review and the experience of specialists of ICET-
A network. Where possible, the recommendations 
are based on and linked to, the evidence that 
supports them, unless good-quality evidence is 
absent. 
 
Methods. The first step- survey was held on the 
19
th
 and 20
th
 of March 2015, in Rome, during the 
10
th
 International Workshop of ICET-A. A 
questionnaire was distributed before the beginning 
of sessions to participants with relevant experience 
in thalassemia care. The answers were collected 
and discussed at the end of the session. The aim of 
the study was to investigate the attitudes and 
prescription habits of doctors concerning HRT in 
TM patients. Exclusion survey criteria included 
patients with thalassemia intermedia. 
The second step survey was administered 
online to the ICET-A members on July 4
th
, 2016. 
An introductory letter explained the purpose of the 
study. The questionnaire consisted of 23 questions, 
namely: personal doctors’ data, place of work, 
specialization, number of female  patients with 
TM followed over the age of 18 years, number of 
TM patients on HRT, type/s of HRT used, the 
patients' compliance to treatment, the speciality of 
the physician recommending HRT, opinions on 
indications and contraindications for HRT use 
among doctors and  types and number of tests used  
during patients' follow-up.  
After collection and analysis of data, the ICET-
A Steering Committee (VDS, ATS, HE, MEK, 
SDM, CK) prepared (third step) practical 
recommendations for the management of these 
patients. In making these recommendations, 
experts considered the differences in countries’ 
facilities, general cost of tests and recommended 
management of hypogonadism. The ICET- A 
members were asked to provide comments on the 
accuracy, feasibility, and approval of the 
recommendations. 
 
Results 
First step: Twenty-five questionnaires were 
distributed, and 24 (96%) were answered. The 
participants included ten pediatricians, four 
endocrinologists, and ten hematologists.They were 
following a total of 2326 females and males with 
TM. 
Twelve different formulations and three routes 
of administration for HRT were used. The 
majority of respondents (33.3%) used ethinyl 
estradiol 30 µg/drospirenone 3 mg as first-line 
treatment choice, (25%) ethinyl estradiol 20 
µg/drospirenone 3 mg. Ethinyl estradiol 35 
µg/cyproterone acetate 2 mg (41.6 %) and ethinyl 
estradiol 20 µg/drospirenone 3 mg (29.1%) were 
reported as second-line treatment choice. 
Transdermal patch, estradiol transdermal plus 
progesterone, and etonogestrel/ethinyl estradiol 
vaginal ring were used and recommended by 
16.6%, 4.1%, and 4.1%, respectively.
7
 
 
Second step: The questionnaires were returned by 
16 of 27 specialists: 6 pediatric endocrinologists, 2 
endocrinologists; 3 pediatric hematologists, 3 
hematologists, 1 pediatrician and 1 general 
practitioner [the majority (75%) were female 
doctors] following 590 female TM patients over 
the age of 18 years; 315 (53.3 %) had 
hypogonadism, and 245 (74.6 %) were on HRT.  
The reported most common  contraindications 
to treatment were: elevation of liver enzymes - 
from 3 to 6 times the normal values ( 62.5%), 
thrombophilia (43.7 %), insulin dependent 
diabetes (25%), insulin dependent diabetes 
associated with vascular complications (6.2 %), 
patient non-compliance to treatment (25%). HRT 
was recommended by endocrinologists in 9  
thalassemia centers, by endocrinologists and 
gynecologists in 6, and by endocrinologist and 
hematologist in 1 center. Responders were asked 
to select the three commonest compounds used as 
HRT. Contraceptive oral pills (COC) were the first 
choice of treatment in 11 centers. A wide range of 
COCs was used with different progestin contents, 
such as drospirenone, dydrogesterone, norgestrel, 
norethisterone, gestodene, desogestrel, 
medroxyprogesterone acetate, micronized 
progesterone soft gelatin capsules. In 6 Centres 
transdermal estrogen patch in combination with 
oral progesterone was given as the first choice of 
treatment. In general, patients' compliance to 
treatment was reported as good in 81.2 % of 
Centres.  
The frequency and number of required tests during 
follow-up, in addition to the regular check-up for 
thalassemia, varied in the participating Centres 
(even in centers within the same country). The 
results for each Centre participating in the survey 
are reported in Table 1. 
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Table 1. Frequency of required tests during follow-up of TM patients with hypogonadism on HRT. 
 
Liver 
enzymes 
Serum 
glucose 
OGTT 
Clotting 
factors 
Lipids 
Renal 
function 
BMD 
Pelvic 
ultrasound 
Other tests 
Cyprus 
3 
months 
3 
months 
12 
months 
12 
months 
12 
months 
3 
Months 
12 
Months 
12 
months 
NR 
Egypt 
3 
months 
3  
months 
12 
months 
when 
indicated 
when 
indicated 
3 
Months 
Research 
basis 
when 
indicated 
FSH, LH and  
Estradiol 
Egypt NR 
6 
months 
nil Nil nil Nil 
2 
Years 
NR NR 
India 
3-6 
months 
12 
months 
nil Nil 
24 
months 
12 
Months 
Nil NR NR 
Italy monthly monthly 
24 
months 
6 
months 
3 
months 
monthly 
12-24 
Months 
12 
months 
EcoCG 
ECG 
Italy 
3 
months 
6 
months 
24-36 
months 
12 
months 
12 
months 
6 
Months 
24 
Months 
12 
months 
NR 
Italy monthly 
2 
months 
12 
months 
6 
months 
3 
months 
12 
Months 
12 
Months 
12 
months 
Cardiac T2* 
Italy monthly 
3 
months 
12-24 
months 
6-12 
months 
6-12 
months 
6-12 
Months 
12-24 
Months 
12 
months 
Cardiac T2* 
HOMA-IR  § 
A-US  every 12 
months 
Italy 
2 
months 
3 
months 
when 
indicated 
3 
months 
3 
months 
2 
Months 
12-18 
Months 
12 
months 
NR 
Italy 
3 
months 
3 
months 
3 
months 
3 
months 
6 
months 
3 
Months 
12 
Months 
12 
months 
NR 
Italy 
6 
months 
6 
months 
24 
months 
6 
months 
12 
months 
6 
Months 
24 
Months 
12 
months 
NR 
Kingdom 
of Saudi 
Arabia  
3-4 
months 
3-4 
months 
12 
months 
6 
months 
12 
months 
3-4 
Months 
12 
months 
when 
indicated 
Cardiac T2* if 
needed 
Oman 
1-6 
months 
6 
months 
12 
months 
Nil 
12 
months 
1-6 
Months 
24-36 
months 
12 
months 
FSH, LH, and 
estradiol. 
Liver T2* at least 
yearly, A-US 
yearly 
Romania 
12 
months 
nil 
12 
months 
Nil 
12 
months 
2 
Months 
12 
months 
12 
months 
NR 
Turkey 
1-3  
months 
3  
months 
6 
months 
12 
months 
12 
months 
monthly 
12 
months 
when 
indicated 
FSH, LH and  
Estradiol 
Turkey 
3  
months 
3  
months 
12 
months 
12 
months 
12 
months 
3 
months 
12 
months 
12 
months 
NR 
UK 
2 
months 
6 
months 
12 
months 
4 
months 
6 
months 
2 
Months 
24-36 
months 
nil NR 
Abbreviations. TM - thalassemia major; OGTT- Oral Glucose Tolerance Test; NR- Not reported; HOMA-IR Homeostatic Model Assessment 
of Insulin Resistance- § every 6-12 months; Abdominal A-US- abdominal  ultrasound; EcoCG-Echocardiogram; ECG-Electrocardiogram; 
BMD -Bone Mineral Density 
 
Third step: The ICET-A recommendations for 
hypogonadism in adult females with TM were 
based on published, peer-reviewed scientific 
evidence, expert opinion, and accumulated 
professional knowledge and experience of ICET-A 
network 
specialists. Recommendations from published 
guidelines were used when available and 
appropriate. Original articles for the evidence-
based recommendations were obtained following a 
computer search for ‘hormone replacement’ as a 
keyword and also in combination with ‘venous 
thrombosis’ (VTE) or ‘deep venous thrombosis’ 
(DVT) or ‘pulmonary embolism’ or 
‘thrombophilia’ or "chronic liver disease" or 
"diabetes" applied to Medline. 
The ICET-A Network also issued expert 
consensus opinions on topics for which limited or 
low-level evidence was available in the literature. 
Since not all published references were based on 
randomized controlled trials, the recommendations 
have been scored according to the following 
criteria: 
A. High confidence indicates that further research 
is unlikely to change the confidence in the 
estimate of effect (●●●) 
B. Moderate confidence indicates that further 
research may change the confidence in the 
estimate of effect (●●○) 
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C. Low confidence indicates that further research 
would likely have a significant impact on the 
confidence in the estimate of effect (●○○) 
D. Insufficient indicates that the evidence is 
unavailable or does not permit a conclusion 
(○○○) 
 
Discussion. The goals of substitutive therapy in 
adult female patients with hypogonadism are to 
maintain secondary sexual characteristics, to 
optimize the accrual of bone mineral content and 
to promote physical and social well-being.  
Few trials of the effects and complications of 
estrogen therapy in primary and secondary 
hypogonadism of women at premenopausal age 
have been published and none of TM patients. As 
a consequence of the scanty evidence, 
recommendations for HRT in thalassemia are 
based on publications on the effects and 
complications of COC used for contraception and 
postmenopausal hormone replacement in healthy 
women. 
The three forms of estrogen produced in the 
human body are estrone (E1), estradiol (E2) and 
estriol (E3). The estrogen composition in the 
female body is approximately 3% estrone, 7% 
estradiol, and 90% estriol. The potencies of these 
hormones vary, with estradiol being the most 
potent followed by estrone and estriol.
6,8
 
Sequential estrogen-progestogen replacement 
therapy is the mainstay of treatment for women 
with hypogonadism. Estrogen may be replaced 
using oral, micronized, vaginal, or transdermal 
preparations. Subcutaneous implants and more 
recently, nasal sprays and injectable estrogen 
preparations are also available.  
There are three types of estrogen available for 
hormone replacement: estradiol, ethinylestradiol (a 
synthetic estrogen, EE) and conjugated equine 
estrogens (derived from pregnant mare urine, 
CEE). Major characteristics that differentiate one 
formulation from another include the form of 
estrogen used and its dosage, and the generation of 
the progestin. 
The formulations of COC have changed over 
the past 50 years. The dose of the EE component 
has decreased from the original 100-150 μg to 15 
to 30 μg. These changes were made to lower the 
risk of thromboembolic complications associated 
with the use of oral contraceptive pills.
6
 
In the absence of a consensus regarding the 
ideal hormonal replacement regimen for women 
facing a premature cessation of ovarian function, 
the estroprogestative substitution commonly 
involves either HRT or COC prescription.   
Several studies compared estrogen preparations 
in adult females, but the adolescent and young 
adult population are relatively understudied.
9-12
 A 
recent report in girls with Turner syndrome 
demonstrated more physiologic estrogen 
concentrations with the use of the transdermal 
estrogen preparation versus oral preparations. 
13
 
Ninety percent of the EE is absorbed from the 
upper gastrointestinal tract in 1 to 2 hours, then 
exposed to oxidation. Following absorption, EE is 
metabolized during passage through the 
enterohepatic circulation. EE has a strong hepatic 
impact related to its 17a-ethinyl group. This group 
prevents the inactivation of the EE and results in a 
slow metabolism and prolonged tissue retention. 
EE is much more potent than the naturally secreted 
estrogens because it remains in the blood for a 
longer time after administration and has a greater 
effect on the liver.
8
 
In our survey, the majority of specialists (11 
centers) preferred COCs as the first line of 
treatment COCs of convenience, efficacy and 
patients’ preference and availability. 
COC are classified into different generations 
(first, second, third and fourth), depending on the 
time of introduction into the market. They vary 
regarding the dose of estrogen and the type of 
progestin. Progestins are needed to avoid an 
unopposed estrogen effect and maintain 
endometrial health. Progestins can be administered 
via the oral, transdermal (as a patch), or intra-
uterine routes. Micronized progestogens are 
available to use orally, vaginally and as 
transdermal (cream) preparations. 
Progestins have no selectivity for the various 
steroid receptors. The first progestins developed 
were medroxyprogesterone acetate (MPA) and 
norethisterone enanthate (NET-EN). Shortly after, 
these were followed by its first derivative 
norethisterone acetate (NET-A). Many more 
synthetic progestins have been developed in the 
following years. We now have second, third and 
fourth-generation progestins. Examples are 
levonorgestrel (LNG, 2nd generation), gestodene 
(GES, 3rd generation), and drospirenone (DRSP), 
dienogest (DNG) and trimegestone (TMG), all 
fourth generation. The third-generation progestins 
have minimal impact on blood glucose levels, 
plasma insulin concentrations, and the lipid 
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profile. Thus, they are suitable for use in patients 
with lipid disorders or diabetes.
9-11
 
Contrary to menopausal women, adolescents 
and young female adults with hypogonadism due 
to other pathologic mechanisms as in TM patients, 
the HRT treatment is extremely complex because 
of associated comorbidity (iron overload, the 
presence of thrombophilic status, chronic liver 
disease, impaired glucose tolerance or diabetes 
and cardiovascular disease). In addition, the long- 
term duration of chelation treatment and 
psychosocial patients’ needs enhance the difficulty 
of the management.
1- 4,14-18
 
Taher et al.
17
 reported in a retrospective 
multicentre study, that thromboembolic events 
(TE) occurred in a clinically relevant proportion 
(1.65%) of 8,860 thalassemia patients (75.3% with 
TM). Thromboembolic events were 4.38 times 
more frequent in thalassemia intermedia (TI) than 
in TM patients (p < 0.001). More venous events 
occurred in TI and more arterial events took place 
in TM.  
A survey, done in 9 Italian thalassemia Centres, 
disclosed that 32 patients out of a total of 735 (683 
with TM and 52 TI), had VTE episodes 
corresponding to an incidence of 3.95% and 
9.61%, respectively. Localization of TE varied; 
the main one (16/32) involved the central nervous 
system.
15
 
Patients with TE events presented a higher 
incidence of associated organ dysfunction, such as 
cardiomyopathy, diabetes, liver function 
anomalies, and hypothyroidism than those without 
TE events (50 vs. 13.8%, p  <0.05).
15
 
Haghpanah
 
and Karimi conducted an electronic 
search on PUBMED (MEDLINE), SCOPUS, and 
Google Scholar databases up to January 2011. Out 
of 152 thalassemic patients with cerebral 
thromboembolic events; 48% were 
splenectomized. Nine TM patients had diabetes. 
Activated protein C resistance, decreased protein 
C or protein S or plasminogen level were detected 
in 8 patients.
18
 Inadequate transfusion was 
reported to increase the risk of thrombosis 
secondary to increased release of pro-coagulant 
red cell particles.  
Oral administration of EE leads to 
pharmacologic concentration of the hormone in 
the portal vein before it is metabolized by the 
liver. This first-pass reaction results in an 
increased hepatic production of several hormone 
binding globulins, clotting factors, lipoproteins 
and angiotensinogen. This increase in VTE risk is 
highest during the first year of use. It may vary 
according to the different characteristics of COCs, 
such as estrogen dose, molecule, and type of 
progestins. Whether the type of estrogen molecule 
is associated with different degree of risk for 
venous thrombosis remains controversial.
19,20 
Based on the Women’s Health Initiative (WHI) 
trials, oral conjugated equine estrogen and 2.5 mg 
MPA increased VTE compared with placebo (RR, 
2.06; CI, 1.57–2.70). These findings, however, 
require confirmation.
21,22
 
Newer generation formulations of hormonal 
contraceptives seem to be more thrombogenic than 
those of second-generation.
19,20,22
 Using LNG as 
the reference , VTE rate ratios for other progestins 
were: NET-EN0.98, desogestrel 1.82, GES 1.86, 
DRSP 1.64 and cypropterone (CPA) 1.88.
19,20,22
 
Some observational studies assessed the risk of 
VTE associated with transdermal estrogen therapy 
in non-thalassemic population. The pro-thrombotic 
effects seem to be circumvented by transdermal 
administration of estrogen and, therefore, have 
significant clinical implications.
22
 
The  VTE risk for vaginal ring  or patch is as 
high as for COCs of third or fourth generation. 
22
 
Liver dysfunction in thalassemics is mainly 
attributable to liver siderosis and chronic HCV 
infection (chronic hepatitis C).
23,24
 Furthermore, 
chronic hemolysis in TM favours the  
development of bilirubin gallstones. The incidence 
of gallstones varies considerably in clinical studies 
and is related to age and the efficiency of 
transfusion treatment of studied cohorts. Thirty 
percent of 858 consecutive Italian TM patients had 
chololithiasis diagnosed by abdominal 
ultrasonography or a history of cholecystectomy.
25
 
In addition, chronic application of third generation 
progestogens as contraceptives or HRT could 
influence the serum lipid profile, and consequently 
increase the risk of biliary lithogenicity.
26
 
Although elevation of liver enzymes - from 3 to 
6 times the normal values was the commonest 
contraindication to hormonal treatment reported 
by 10/16 Centres, further studies including liver 
imaging and LIC assessment are needed to clarify 
the role of HRT on liver enzyme levels, metabolic 
variables and liver fat content. 
Insulin dependent diabetes (IDDM) and 
impaired glucose tolerance (IGT) are relatively 
common complications in thalassaemia major 
(ΤΜ) patients with iron overload and sub-optimal 
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chelation therapy. The prevalence of IDDM and 
IGT in adolescents and young adults with TM 
mainly treated with desferrioxamine mesylate 
(DFO) varies considerably in 2 studies ranging 
from 0 to 21% and from 9.3 to 24.3 %, 
respectively.
27,28
 Even higher differences exist in 
other studies depending on the age composition 
and on the efficiency of chelation of  the studied  
TM cohorts. 
Currently, there appear to be wide variations in 
the way that professionals evaluate the risk-benefit 
equation in subjects with IDDM, and significant 
differences in prescribing practice have been 
identified. In women with insulin-dependent or 
non–insulin-dependent diabetes COCs use have 
limited effect on daily insulin requirements and no 
effect on long-term diabetes control or progression 
to retinopathy, if clinical and metabolic 
monitoring can be ensured. COCs must be avoided 
in case of, cardiovascular disease or severe 
microvascular complications such as nephropathy 
with proteinuria or active proliferative 
retinopathy.
29-33
 
The safety of prescription of COCs to women 
with type II diabetes is unclear, but a supervised 
program similar to that of IDDM patients is 
recommended. 
 
Conclusions and Recommendations. Despite the 
large number of patients for whom HRT is 
prescribed, there are no prospective studies of 
treatment and/or recommendations to guide 
clinicians in the application of the optimal 
treatment regimens in patients with TM presenting 
with hypogonadism and complications influenced 
by HRT. Therefore, there is an urgent need to 
develop guidelines based on solid research in 
order to optimize the care of this group of women.  
The United States Medical Eligibility Criteria 
(US MEC) for Contraceptive Use, in July 2016,
33
 
recommended the following medical eligibility 
criteria categories for estrogen/progestin pill, 
hormonal patch and combined vaginal ring:  
1 = A condition for which there is no restriction 
for the use of the contraceptive method.  
2 = A condition for which the advantages of 
using the method generally outweigh the 
theoretical or proven risks.  
3 = A condition for which the theoretical or 
proven risks usually outweigh the advantages of 
using the method. 
4 = A condition that represents an unacceptable 
health risk if the contraceptive method is used.  
No restrictions are reported for 
estrogen/progestin pill, patch or vaginal ring in 
TM patients (category 1). Regarding some other 
pathologies, the US MEC for the contraceptive 
use, reported the following risk categories: an 
increased risk in  the presence of family history 
(1st-degree relatives) for venous thrombosis 
(category 2) and a high risk in presence of past TE 
and known thrombogenic mutations (e.g., factor V 
Leiden; prothrombin mutation; and protein S, 
protein C, and antithrombin deficiencies) 
(category 4); in women with chronic hepatitis, 
COC use does not increase the rate or severity of 
cirrhotic fibrosis, nor does it increase the risk for 
hepatocellular carcinoma (category 1); a small 
increased risk for asymptomatic gallbladder 
disease (category 2), in subjects with gallbladder 
disease treated medically the risk is higher  
(category 3); in women with insulin-dependent or 
non–insulin-dependent diabetes COC use have 
limited effect on daily insulin requirements and no 
effect on long-term diabetes control or progression 
to retinopathy (category 1), in presence of 
associated nephropathy, retinopathy, or 
neuropathy the risk is high (category 4); for 
atherosclerotic cardiovascular diseases (e.g. 
smoking, diabetes, hypertension, low HDL, high 
LDL, or high triglyceride levels) the risk is high 
(category 3/4);  in subjects  with migraine without 
aura or with aura the risk category is 2 and 4, 
respectively. 
On deciding to treat a hypogonadal TM woman 
with estrogen and progestin, consideration must be 
given to the general condition of the patient, 
current chelation therapy and the presence of 
associated complications.
34-36 
To minimise the potential risks of treatment, 
excessively high sex hormonal concentrations 
should be avoided.
36
 The aim is to achieve, in 
regularly menstruating women the typical mean 
serum estradiol levels of approximately 100 pg/ml 
(400 pmol/l).
37
 Transdermal administration of 25-
50 µg 17β estradiol generally produces in TM 
patients a plasma E2 value in the early to mid-
follicular phase range (100-300 pmol/l).
36
 
Progesterone is usually given at for 12-14 days 
each month to bring on a menstrual withdrawal 
bleed. Micronized progesterone is composed of 
smaller particles that may aid in absorption. It was 
proposed as first-line progestin because there are 
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reasons to believe that natural progesterone might 
be safer for the cardiovascular system (no adverse 
lipid effects) and possibly the breast, although the 
strongest evidence for endometrial protection is 
for oral cyclical combined treatment.
34,35,37-39
 
The potential effects of HRT demand that 
doctors taking care of TM patients have a sound 
knowledge of the benefits and disadvantages of 
estrogens and progesterone. They must also 
possess comprehensive knowledge of female 
reproductive biology and particular sensitivity to 
the emotional needs of these patients. Current 
guidelines in patients with premature ovarian 
failure suggest that therapy should be continued 
until the average age of menopause (age 50 to 51 
years) to prevent premature bone loss, coronary 
heart disease, and stroke.
40,41
 
Because HRT in patients with chronic diseases 
is a complex task, the ICET-A prepared some 
relative recommendations for HRT in TM patients 
and its monitoring (Tables 2 and 3), based on the 
data reported in the literature for adolescent and 
young women without TM, for HRT with sex 
steroids. Further research consortia are needed to 
investigate these important questions, and to assist 
clinicians in making the best possible health care 
approach for the adolescents and young women 
with TM and hypogonadism. 
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Table 2. The ICET-A recommendations for female TM patients with hypogonadism. 
 Iron status (including LIC and cardiac T2*) should be assessed before treatment in order to evaluate its clinical relevance, the 
need for treatment, and the timing and monitoring of chelation therapy (●●●). 
 Intensive iron chelation therapy is recommended in iron overloaded patients before treatment (●●●). 
 Doctors should weigh the risks against the benefits when prescribing combination estrogen plus progestin hormone therapy and 
counsel the patient accordingly (●●●). 
 Before starting HRT, each patient should be carefully screened by a physician who should identify an increased risk of 
thrombophilia and tailor the laboratory testing (●●●). 
 In TM patients with a known thrombophilic defect (such as deficiency of antithrombin, protein C or protein S) that has been 
identified through screening the pros and cons of  HRT treatment should be discussed with a specialist (●●○). In TM patients 
with a history of VTE, HRT must be avoided (●●○). 
 Transdermal estradiol and micronized progesterone seem to be the most "physiologic regimen" with the best safety profile, 
particularly in women with risk factors for VTE (●●○). Natural progesterone may have a more favorable cardiovascular profile 
and possibly a reduced risk of breast cancer, although the strongest evidence for endometrial protection is for oral cyclical 
combined treatment (●●○). 
 Transdermal patches may result in local skin irritation, and some find them difficult to keep in place (●●○). Advice on correct 
positioning and rotation of application sites may help. However, if compliance is not fit or if contraception is required, the use of 
the COC is a reasonable choice (●○○). 
 Splenectomized TM patients with hypogonadism on HRT should receive antiplatelet or anticoagulant therapy with aspirin or low 
dose warfarin (●●○). 
 There are no studies on the effect of HRT on lipids, and little information on bone densitometry in hypogonadal TM women on 
HRT (●○○). 
 HRT is contraindicated in acute liver disease. However, once the episode of acute illness has entirely passed, HRT may be 
initiated (●●○). 
 Treatment of chronic hepatitis C with new antiviral drugs, and intensive chelation in those with severe liver siderosis (LIC > 7 
mg/dry weight) prior to HRT is recommended (●●●).  
 Limited data from studies on chronic hepatitis or its sequelae in non-TM patients suggest that COC use does not influence the 
progression or severity of liver fibrosis or development of hepatocellular carcinoma (●○○). 
 If the serum liver enzymes after one month of HRT rise by more than 100 %, or if baseline serum bilirubin is elevated, liver 
biochemistry should be repeated monthly for at least three months, and treatment needs to be reconsidered (●○○). 
 Chronic use of third generation contraceptives or HRT could influence the serum lipid profile, and consequently cause an 
increase in bile lithogenicity (●○○). 
 In women with insulin-dependent or non–insulin-dependent diabetes COCs use has a limited effect on daily insulin requirements 
and no effect on long-term diabetes control or progression to retinopathy. COCs must be avoided in case of severe microvascular 
complications such as nephropathy with proteinuria or active proliferative retinopathy (●●○).  
 Young and adult women with hypogonadism should be counseled as to alcohol and tobacco avoidance, daily exercise for obesity 
prevention, and an appropriate diet to achieve optimal cardiovascular health (●●○). 
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Table 3. The ICET-A guidelines for the monitoring of HRT in female TM patients with hypogonadism. 
 
Start of treatment 
(baseline) 
Each visit 3-6 Months Yearly 1–2 years 
Physical examination and compliance 
Blood pressure and  Tanner's stage assessment 
Pelvic exam in sexually active patients 
√ 
√ 
√ 
√ 
 
 
√ 
 
 
√ 
 
Assessment of iron overload (*) √  √   
Basal FSH, LH and 17β estradiol levels and thyroid status 
Pelvic and abdominal US 
√   √  
Renal and liver function 
Fasting lipids 
√ 
√ 
  
√ 
√ 
 
Family and personal history of VTE and Thrombophilia 
screening 
√   √  
Basal  glucose and insulin glucose and HOMA-IR assessment  
Oral glucose tolerance test (OGTT) 
√ 
In selected cases 
 
√ 
 
 
√ 
 
BMD of lumbar spine/femoral neck √    √ 
Abbreviations. HOMA-IR Homeostatic Model Assessment of Insulin Resistance; BMD- bone mineral density; US-ultrasound; *Serum 
ferritin levels every three months, Magnetic Resonance Imaging (Liver iron concentration -LIC) at baseline and in one year if LIC >7mg/ 
and in two years if LIC < 7mg). 
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